Stereotaxis, Inc. STXS
Set alert
As of Nov 3, 10:13 AM ET
- YTD
- -61.67%
- 1 year
- -68.28%
- Open
- 0.8848
- Prev close
- 0.8801
- Mkt cap
- 88.22M
- Vol
- 56.26K
- Avg vol
- 584.40K
- EPS
- -0.24
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.8802
- High
- 0.903
- Forward P/E
- -13.06
- Beta
- 1.55
- Short ratio
- 6.26
- Inst. own
- 48.48%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.08
- 200-d avg
- 2.14
- 1y target
- 4.50
News
-
1 day ago benzinga.com
Stereotaxis Announces 100% Clinical Success Rate For Its Robocath's Robotic System At Transcatheter Cardiovascular Therapeutics Conference; Technical Success Reported At 95%
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the findings from the first-in-human clinical results for…
1 day ago globenewswire.com
First-in-Human Coronary Intervention Study Results of Robocath's Next-Generation Robotic System Highlighted at TCT
ST. LOUIS and ROUEN, France, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today…
-
4 days ago benzinga.com
Canon Medical Systems, Stereotaxis Announce Technology Compatibility And Commercial Collaboration To Pair Alphenix Interventional Imaging Platform With Genesisx Robotic Magnetic Navigation System
Collaboration brings together Canon’s Alphenix interventional fluoroscopy system and Stereotaxis’ GenesisX robotic technologyTechnologies will be presented at TCT 2026 in the Canon boothTUSTIN,…
4 days ago globenewswire.com
Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology
Collaboration brings together Canon's Alphenix interventional fluoroscopy system and Stereotaxis' GenesisX robotic technology Technologies will be presented at TCT 2026 in the Canon booth TUSTIN,…
-
1 week ago benzinga.com
Stereotaxis Says Pauls Stradiņš Clinical University Hospital In Latvia, Establishes Robotic Center For Treatment Of Cardiac Arrhythmias In Latvia And Treats Initial Patients With Genesis Robotic Magnetic Navigation System
Pauls Stradiņš Clinical University Hospital installs Genesis Robotic Magnetic Navigation System, establishing the first robotic program for the treatment of cardiac arrhythmia in LatviaFirst…
-
2 months ago benzinga.com
Citizens Maintains Market Outperform on Stereotaxis, Lowers Price Target to $3
Citizens analyst Daniel Stauder maintains Stereotaxis (AMEX:STXS) with a Market Outperform and lowers the price target from $4 to $3.
-
2 months ago benzinga.com
TD Cowen Maintains Buy on Stereotaxis, Lowers Price Target to $3
TD Cowen analyst Joshua Jennings maintains Stereotaxis (AMEX:STXS) with a Buy and lowers the price target from $5 to $3.
-
2 months ago benzinga.com
Stereotaxis Q2 EPS $(0.05) Beats $(0.06) Estimate, Sales $7.670M Miss $8.350M Estimate
Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is unchanged from the same period last year. The…
3 months ago benzinga.com
Why Callan JMB Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Callan JMB Inc (CJMB) shares jumped 63.8% in pre-market trading after announcing a strategic partnership with Alabama State University.
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-market session. The company's market cap stands at $3.3 million. Stereotaxis (AMEX:STXS) stock increased…
-
5 months ago benzinga.com
Piper Sandler Reiterates Overweight on Stereotaxis, Lowers Price Target to $3.5
Piper Sandler analyst Adam Maeder reiterates Stereotaxis (AMEX:STXS) with a Overweight and lowers the price target from $4 to $3.5.
5 months ago benzinga.com
Stereotaxis Q1 2026 Earnings Call Transcript
Stereotaxis Q1 2026 Earnings Call Transcript
-
5 months ago benzinga.com
Stereotaxis Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $6.291M Miss $8.620M Estimate
Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. This is a 14.29 percent increase over losses of $(0.07)…
6 months ago benzinga.com
Stereotaxis Eyes Billions In Market Opportunity With Robocath Takeover
Stereotaxis to acquire Robocath, advancing robotic endovascular tech and accelerating expansion into cardiology and neuro markets.
-
6 months ago benzinga.com
Stereotaxis To Acquire Robocath, A Venture-Backed Producer Of Robotic Technologies For Interventional Cardiology And Neurointerventions; Terms Not Disclosed
This acquisition significantly strengthens Stereotaxis' position as a leading platform for the full spectrum of endovascular procedures, combining complementary technologies to deliver…
-
7 months ago benzinga.com
Stereotaxis Receives FDA 510(k) Clearance For Synchrony System
Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration…
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
7 months ago benzinga.com
STX Semiconductor Co. Files Prospectus To Offer Up To $100M In Debt, Equity, Warrants, Rights, And Units
$100,000,000 Debt SecuritiesCommon StockPreferred StockWarrantsRightsUnitsWe may offer and sell from time to time, in one or more offerings, up to $100,000,000 in the aggregate of debt securities,…
7 months ago benzinga.com
Stereotaxis Q4 Earnings Summary & Key Takeaways
Stereotaxis Q4 Earnings Summary & Key Takeaways
-
7 months ago benzinga.com
Stereotaxis Q4 EPS $(0.06), Inline, Sales $8.642M Miss $9.080M Estimate
Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 33.33 percent increase over losses of $(0.09) per share from the same period…
-
10 months ago benzinga.com
This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
-
10 months ago benzinga.com
Citizens Initiates Coverage On Stereotaxis with Market Outperform Rating, Announces Price Target of $4
Citizens analyst Daniel Stauder initiates coverage on Stereotaxis (AMEX:STXS) with a Market Outperform rating and announces Price Target of $4.
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
11 months ago benzinga.com
Stereotaxis Q3 EPS $(0.07) Misses $(0.06) Estimate, Sales $7.464M Miss $8.375M Estimate
Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 12.5 percent increase over losses of $(0.08)…
11 months ago benzinga.com
Earnings Scheduled For November 11, 2025
Earnings Scheduled For November 11, 2025
-
11 months ago benzinga.com
Stereotaxis Granted FDA 510(k) For Its GenesisX RMN System With Navigant Workstation And Cardiodrive As Substantially Equivalent
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K251792
-
11 months ago benzinga.com
A Look at Stereotaxis's Upcoming Earnings Report
A Look at Stereotaxis's Upcoming Earnings Report
-
1 year ago benzinga.com
Stereotaxis Receives CE Mark, Seeks FDA Approval for Synchrony Surgical Robotics System
Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE Mark in Europe and submitted a 510(k)…
1 year ago benzinga.com
New Robotic System Promises Faster, Safer Care For Arrhythmia Patients
Stereotaxis (AMEX: STXS) announces first procedures with Genesis Robotic Magnetic Navigation System for minimally invasive endovascular interventions.
-
1 year ago benzinga.com
Stereotaxis' Genesis Robotic Magnetic Navigation System Used In First Procedures By Physicians At Erasmus University MC In Netherlands
Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced successful first procedures by physicians at Erasmus…
-
1 year ago benzinga.com
Stereotaxis Q2 EPS $(0.05) Beats $(0.07) Estimate, Sales $8.798M Beat $7.750M Estimate
Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 30.56 percent. This is a 28.57 percent increase over losses of $(0.07)…
-
1 year ago benzinga.com
Stereotaxis Receives FDA 510(k) Clearance For MAGiC Sweep Catheter
Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration…
-
1 year ago benzinga.com
Stereotaxis Announces $12.5M Registered Direct Offering Of Common Stock At $2.00 Per Share
Led by Strategic Industry Partner and Select Institutional InvestorsProceeds Strengthen Balance Sheet and Support Commercialization of Innovation Strategy
-
1 year ago benzinga.com
Stereotaxis Q1 EPS $(0.07), Inline, Sales $7.47M Beat $6.88M Estimate
Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 16.67 percent decrease over losses of $(0.06) per share from the same period…
1 year ago benzinga.com
What's Going On With Stereotaxis Shares Wednesday?
Stereotaxis shares are moving higher on Wednesday after the company announced it was accepted into the NVIDIA Connect program.
-
1 year ago benzinga.com
Stereotaxis Q4 EPS $(0.09) Misses $(0.07) Estimate, Sales $6.34M Miss $6.42M Estimate
Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 28.57 percent decrease over losses of $(0.07)…
-
1 year ago benzinga.com
Stereotaxis Submits First Robotic Catheter for FDA Approval to Expand Endovascular Surgery
Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced FDA regulatory submission for the first robotically…
-
1 year ago benzinga.com
Stereotaxis Receives European CE Mark Approval For MAGiC Ablation Catheter, Enhancing Robotics In Electrophysiology With Advanced Navigation, Improved Data, And Low-Flow Cooling Benefits
Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received European CE Mark approval for the MAGiC™…
-
1 year ago benzinga.com
Stereotaxis' Genesis Robotic System Debuts in Finland, Treats First Patients
Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Oulu University Hospital in Finland have…
-
1 year ago benzinga.com
Stereotaxis and MicroPort EP Secure NMPA Approval for Magbot Ablation Catheter in China
Stereotaxis (NYSE:STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, "MicroPort EP"), today announced that the Magbot™ Magnetic Navigation Ablation Catheter has received regulatory…
-
1 year ago benzinga.com
Stereotaxis Announces That Physicians At The Hospital Da Luz In Lisbon, Portugal Have Successfully Treated The First Patients Using The Advanced Genesis Robotic Magnetic Navigation System
Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the Hospital da Luz in Lisbon, Portugal…
-
1 year ago benzinga.com
Stereotaxis Q3 2024 GAAP EPS $(0.08) Misses $(0.05) Estimate, Sales $9.196M Beat $7.100M Estimate
Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.05) by 60 percent. The company reported quarterly sales of $9.196 million…
-
1 year ago benzinga.com
Earnings Scheduled For November 11, 2024
Earnings Scheduled For November 11, 2024